ArticleCancer medicine2026
Hypothyroidism as Prognostic Factor in Cutaneous Melanoma: A 1553-Patient Single-Center Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCutaneous melanoma is a rising global health concern and identifying modifiable or associated risk factors remains essential for improving prognostic stratification. Hypothyroidism, affecting approximately 5.1% of the general population in Germany, has been associated with various malignancies. This study investigates the prevalence and potential prognostic implications of hypothyroidism in melanoma patients.
methodsWe conducted a retrospective single-centre study including 1553 patients with cutaneous melanoma (AJCC stages I-III). Patients were stratified based on thyroid function into hypothyroid and euthyroid groups. Data were collected via clinical records and standardized patient questionnaires.
resultsHypothyroidism was documented in 234 patients (15.1%), significantly higher than the national prevalence (5.1%, p < 0.001). Tumor site differed significantly between groups, with hypothyroid patients more frequently exhibiting melanomas on the lower extremities (p < 0.001). These patients also showed a non-significant trend toward lower Breslow thickness (p = 0.09) and a significantly reduced number of metastatic lymph nodes (p = 0.009).
conclusionsOur findings suggest that hypothyroidism is markedly more prevalent among patients with cutaneous melanoma and may be associated with clinical features linked to improved prognosis. These observations warrant further investigation to clarify whether hypothyroidism itself, or its underlying immunologic and hormonal milieu, plays a protective role in melanoma progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.